Treatment guidelines for scleroderma (SSc) have evolved since the turn of the century with advances in scientific understanding and the advent of new therapies. In line with these evolving guidelines, patterns of therapies prescribed to people with SSc have shifted markedly since 2000, according to a new analysis from…
News
Blood levels of a protein called KL-6 may help identify people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who are at greater risk of short-term lung function decline, according to a new analysis of data from a Phase 3 clinical trial. Among participants who received a placebo in the…
People with scleroderma (SSc) who don’t show the so-called scleroderma pattern, a common diagnostic finding of small blood vessel damage associated with the condition, may experience a milder course of the disease, an Italian study suggests. About 5% of study participants didn’t show this characteristic pattern at the time…
Scientists at Northwestern University have developed a wireless sensor that may help monitor skin stiffness in conditions such as scleroderma from home. “The great thing about the sensor is it’s small, the potential for home use is tremendous, and for patients who know that they are at risk and…
People living with scleroderma are being invited to take part in a new survey designed to better understand how the chronic autoimmune disease affects their daily lives. The findings may help guide future research and, ultimately, improve patient care. The Scleroderma Health and Resources Survey, launched by the…
Scleroderma is now part of a federal program that aims to help understand underlying mechanisms and develop new treatments and diagnostic targets for autoimmune conditions. The Foundation for the National Institutes of Health (FNIH) has expanded its Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program,…
An investigational off-the-shelf, or readily available, CAR T-cell therapy has shown early signs of effectiveness — with clinical improvements and no serious safety concerns — in the first four people with systemic sclerosis (SSc) treated in an ongoing clinical trial in the U.S. and Europe. That’s according to preliminary…
A clinical trial will study investigational therapies in people at the earliest stages of systemic sclerosis (SSc), before irreversible organ damage has occurred. Contract research organization Indero and the World Scleroderma Foundation (WSF) are partnering on the trial, called WSF SHIELD. It will test multiple investigational therapies in…
Off-label treatment with JAK inhibitors appeared to keep lung function stable and reduce skin thickening, joint pain, and swelling in a small real-world study of systemic sclerosis (SSc). They also caused some side effects and their use needs further confirmation in larger controlled studies, researchers wrote. The study, “…
People with scleroderma who are triple autoantibody-negative — meaning they don’t have three common disease-associated antibodies — are more likely to experience muscle damage and lung disease than others with the rare condition, a new study shows. Conversely, data indicate that patients negative for the three antibodies are less…
Recent Posts
- New anti-scarring pill shows encouraging safety in early trial
- No-touch light test may help in monitoring scleroderma skin changes
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track
- Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
- John Stamos to be honored for longtime support of scleroderma research